CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 24, 2004
Result type: Reports
Project Number: SR0019-000
Product Line: Reimbursement Review

Generic Name: Dutasteride

Brand Name: Avodart

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Prostatic hyperplasia, benign

Indications: Prostatic hyperplasia, benign

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 20, 2005

Recommendation Type: List in a similar manner to other drugs in class